Nrx Pharmaceuticals Inc (NRXP) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Nrx Pharmaceuticals Inc (NRXP) following the 2026 Q2 hedge fund 13F filings?

As of today, NRXP has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NRXP gained -20.0% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Nrx Pharmaceuticals Inc (NRXP)

33 + Investors. Track Smart Money conviction in NRXP. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — NRXP

Based on 33 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds added NRXP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

33 hedge funds hold NRXP right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +43% more funds vs a year ago

fund count last 6Q

+10 new funds entered over the past year (+43% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 67% buying

24 buying12 selling

Last quarter: 24 funds were net buyers (11 opened a brand new position + 13 added to an existing one). Only 12 were sellers (4 trimmed + 8 sold completely). A clear majority buying is a strong confirmation signal.

➡️

Steady new buyers — ~11 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 5 → 5 → 7 → 11. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔄

Mostly new holders — 52% entered in last year

■ 3% conviction (2yr+) ■ 45% medium ■ 52% new

Only 1 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares +21%, value -5%

Value

-5%

+20%

Last quarter: funds added +21% more shares while total portfolio value only changed -5%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

5 → 5 → 5 → 7 → 11 new funds/Q

New funds entering each quarter: 5 → 5 → 7 → 11. A growing number of institutions are discovering NRXP each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🌱

Early stage — 62% of holders entered in last year

■ 0% veterans ■ 38% 1-2yr ■ 62% new

Of 37 current holders: 23 (62%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 10% AUM from top-100

10% from top-100 AUM funds

9 of 31 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

4.8

out of 10

Moderate Exit Risk

Exit risk score 4.8/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	33	29	13.79%
13F Shares	6M	5M	21.65%
Total Value	$14M	$14M	-4.51%
New Positions	11	6	+5
Increased Positions	13	8	+5
Closed Positions	7	3	+4
Reduced Positions	2	10	-8
Total Calls	4	3	33.33%
Total Puts	2	0	100%
PUT/CALL Ratio	0.5	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

13.79%

13F Shares

21.65%

Total Value

$14M

-4.51%

New Positions

Increased Positions

Closed Positions

Reduced Positions

-8

Total Calls

33.33%

Total Puts

100%

PUT/CALL Ratio

0.5

0.0

Bullish

Institutional Holders (2026 Q2)

33 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in NRXP. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 NRXP holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	B Group, Inc.	7.86%	4,091,767	$16.7M
2	AdvisorShares Investments LLC	0.33%	659,018	$2.7M
3	One Wealth Management Investment & Advisory Services, LLC	0.19%	43,309	$177K
4	Sjbenen Advisory, LLC	0.03%	15,000	$58K
5	Persistent Asset Partners Ltd	0.02%	16,326	$67K
6	Bleakley Financial Group, LLC	0.01%	117,216	$479K
7	Balyasny Asset Management L.P.	0.00%	893,864	$3.7M
8	Chicago Partners Investment Group LLC	0.00%	46,388	$191K
9	Ethos Financial Group, LLC	0.00%	15,900	$51K
10	Commonwealth Equity Services, LLC	0.00%	454,418	$1.9M
11	Global Retirement Partners, LLC	0.00%	33,300	$136K
12	Quadrature Capital Ltd	0.00%	43,605	$178K
13	XTX Topco Ltd	0.00%	18,545	$76K
14	Ameriprise Financial Inc	0.00%	928,728	$3.8M
15	Hrt Financial LP	0.00%	100,724	$411K
16	Marshall Wace, LLP	0.00%	194,580	$796K
17	ExodusPoint Capital Management, LP	0.00%	19,308	$79K
18	SBI Securities Co., Ltd.	0.00%	5,101	$21K
19	Tower Research Capital LLC (TRC)	0.00%	3,884	$16K
20	Citadel Advisors LLC	0.00%	680,043	$2.8M
21	Cresset Asset Management, LLC	0.00%	15,000	$61K
22	UBS Group AG	0.00%	423,115	$1.7M
23	Renaissance Technologies LLC	0.00%	38,600	$158K
24	Vanguard Fiduciary Trust Co	0.00%	182,718	$747K
25	Vanguard Capital Management LLC	0.00%	1,618,159	$6.6M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Nrx Pharmaceuticals Inc (NRXP)

What does the Smart Money Trend signal show for NRXP?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added NRXP than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for NRXP?

More buyers than sellers — 67% buying: Last quarter: 24 funds were net buyers (11 opened a brand new position + 13 added to an existing one). Only 12 were sellers (4 trimmed + 8 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for NRXP holders?

Smaller funds dominant — 10% AUM from top-100: 9 of 31 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held NRXP?

Mostly new holders — 52% entered in last year: Only 1 funds (3%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Nrx Pharmaceuticals Inc (NRXP) following the 2026 Q2 hedge fund 13F filings?

As of today, NRXP has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), NRXP has gained -20.0% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Nrx Pharmaceuticals Inc (NRXP)

Smart Money Signals — NRXP

Buying streak — 4 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +43% more funds vs a year ago

More buyers than sellers — 67% buying

Steady new buyers — ~11 new funds per quarter

Mostly new holders — 52% entered in last year

Buying through price weakness — shares +21%, value -5%

Growing discovery — still being found

Early stage — 62% of holders entered in last year

Smaller funds dominant — 10% AUM from top-100

Institutional Sentiment Summary — NRXP

Hedge Fund Ownership: NRXP

Market Analysis: NRXP

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: NRXP

Is It Too Late to Buy Nrx Pharmaceuticals Inc (NRXP) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: NRXP

Statistics: NRXP

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Nrx Pharmaceuticals Inc (NRXP)

Welcome to 13Foresight!